Keywords: UK, NICE, Zytiga, Prostate cancer, Jansse, Johnson & Johnson, Cancer Research UK

NICE issues negative guidance for Zytiga

Article | 02 February 2012

Print This

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft guidance not recommending the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in